Refractory Angina Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Refractory Angina Market to 2027 - Global Analysis and Forecasts by Drugs ( Estrogen, Nicorandil, Ivabradibe, Ranolazine and L-arginine ); Therapies ( Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation. )

Report Code: TIPRE00003831 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
MARKET INTRODUCTION
Refractory Angina is a disabling chronic heart pain, when the blood flow slows down and makes it hard for the oxygen-rich blood to reach the heart. It refers to a debilitating cardiovascular condition characterized by the inability of arteries to supply the desired blood to the heart

MARKET DYNAMICS
The Refractory Angina Market is anticipated to grow in the forecast period owing to driving factors such increasing prevalence of cardio diseases, research activities aimed at development of newer drugs, increased expenditure on healthcare, and rising awareness. Nevertheless, the negative impact on the public sentiments due to failed therapies may hamper the market growth during the forecast period.

MARKET SCOPE
The "Global Refractory Angina Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Refractory Angina Market with detailed market segmentation by Drugs, Therapies and geography. The global Refractory Angina Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Refractory Angina Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Refractory Angina Market is segmented on the basis of Drugs and Therapies. Based on drugs the market is segmented into Estrogen, Nicorandil, Ivabradibe, Ranolazine and L-arginine. Based on Therapies the market is segmented into Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Refractory Angina Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Refractory Angina Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Refractory Angina Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Refractory Angina Market in these regions.

MARKET PLAYERS
The reports cover key developments in the Refractory Angina Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Refractory Angina Market are anticipated to lucrative growth opportunities in the future with the rising demand for Refractory Angina Market in the global market. Below mentioned is the list of few companies engaged in the Refractory Angina Market.

The report also includes the profiles of key Refractory Angina Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Ark Therapeutics Group plc
  • Neovasc Inc
  • Saneron CCEL Therapeutics, Inc
  • Vasomedical, Inc
  • Cryopraxis
  • Workhardt
  • Synokem
  • Grandix Pharmaceuticals
  • Bluecross
  • Virginia Spine Institute
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Refractory Angina Market - By Drugs
1.3.2 Refractory Angina Market - By Therapies
1.3.3 Refractory Angina Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. REFRACTORY ANGINA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. REFRACTORY ANGINA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. REFRACTORY ANGINA MARKET - GLOBAL MARKET ANALYSIS
6.1. REFRACTORY ANGINA - GLOBAL MARKET OVERVIEW
6.2. REFRACTORY ANGINA - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. REFRACTORY ANGINA MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. ESTROGEN
7.3.1. Overview
7.3.2. Estrogen Market Forecast and Analysis
7.4. NICORANDIL
7.4.1. Overview
7.4.2. Nicorandil Market Forecast and Analysis
7.5. IVABRADIBE
7.5.1. Overview
7.5.2. Ivabradibe Market Forecast and Analysis
7.6. RANOLAZINE AND L-ARGININE
7.6.1. Overview
7.6.2. Ranolazine and L-arginine Market Forecast and Analysis
8. REFRACTORY ANGINA MARKET - REVENUE AND FORECASTS TO 2027 - THERAPIES
8.1. OVERVIEW
8.2. THERAPIES MARKET FORECASTS AND ANALYSIS
8.3. ENHANCED EXTERNAL COUNTERPULSATION AND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION.
8.3.1. Overview
8.3.2. Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation. Market Forecast and Analysis
9. REFRACTORY ANGINA MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Refractory Angina Market Overview
9.1.2 North America Refractory Angina Market Forecasts and Analysis
9.1.3 North America Refractory Angina Market Forecasts and Analysis - By Drugs
9.1.4 North America Refractory Angina Market Forecasts and Analysis - By Therapies
9.1.5 North America Refractory Angina Market Forecasts and Analysis - By Countries
9.1.5.1 United States Refractory Angina Market
9.1.5.1.1 United States Refractory Angina Market by Drugs
9.1.5.1.2 United States Refractory Angina Market by Therapies
9.1.5.2 Canada Refractory Angina Market
9.1.5.2.1 Canada Refractory Angina Market by Drugs
9.1.5.2.2 Canada Refractory Angina Market by Therapies
9.1.5.3 Mexico Refractory Angina Market
9.1.5.3.1 Mexico Refractory Angina Market by Drugs
9.1.5.3.2 Mexico Refractory Angina Market by Therapies
9.1.5.4 US Refractory Angina Market
9.1.5.4.1 US Refractory Angina Market by Drugs
9.1.5.4.2 US Refractory Angina Market by Therapies
9.2. EUROPE
9.2.1 Europe Refractory Angina Market Overview
9.2.2 Europe Refractory Angina Market Forecasts and Analysis
9.2.3 Europe Refractory Angina Market Forecasts and Analysis - By Drugs
9.2.4 Europe Refractory Angina Market Forecasts and Analysis - By Therapies
9.2.5 Europe Refractory Angina Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Refractory Angina Market
9.2.5.1.1 Germany Refractory Angina Market by Drugs
9.2.5.1.2 Germany Refractory Angina Market by Therapies
9.2.5.2 France Refractory Angina Market
9.2.5.2.1 France Refractory Angina Market by Drugs
9.2.5.2.2 France Refractory Angina Market by Therapies
9.2.5.3 Italy Refractory Angina Market
9.2.5.3.1 Italy Refractory Angina Market by Drugs
9.2.5.3.2 Italy Refractory Angina Market by Therapies
9.2.5.4 Spain Refractory Angina Market
9.2.5.4.1 Spain Refractory Angina Market by Drugs
9.2.5.4.2 Spain Refractory Angina Market by Therapies
9.2.5.5 United Kingdom Refractory Angina Market
9.2.5.5.1 United Kingdom Refractory Angina Market by Drugs
9.2.5.5.2 United Kingdom Refractory Angina Market by Therapies
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Refractory Angina Market Overview
9.3.2 Asia-Pacific Refractory Angina Market Forecasts and Analysis
9.3.3 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Drugs
9.3.4 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Therapies
9.3.5 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Refractory Angina Market
9.3.5.1.1 Australia Refractory Angina Market by Drugs
9.3.5.1.2 Australia Refractory Angina Market by Therapies
9.3.5.2 China Refractory Angina Market
9.3.5.2.1 China Refractory Angina Market by Drugs
9.3.5.2.2 China Refractory Angina Market by Therapies
9.3.5.3 India Refractory Angina Market
9.3.5.3.1 India Refractory Angina Market by Drugs
9.3.5.3.2 India Refractory Angina Market by Therapies
9.3.5.4 Japan Refractory Angina Market
9.3.5.4.1 Japan Refractory Angina Market by Drugs
9.3.5.4.2 Japan Refractory Angina Market by Therapies
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Refractory Angina Market Overview
9.4.2 Middle East and Africa Refractory Angina Market Forecasts and Analysis
9.4.3 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Drugs
9.4.4 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Therapies
9.4.5 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Refractory Angina Market
9.4.5.1.1 South Africa Refractory Angina Market by Drugs
9.4.5.1.2 South Africa Refractory Angina Market by Therapies
9.4.5.2 Saudi Arabia Refractory Angina Market
9.4.5.2.1 Saudi Arabia Refractory Angina Market by Drugs
9.4.5.2.2 Saudi Arabia Refractory Angina Market by Therapies
9.4.5.3 U.A.E Refractory Angina Market
9.4.5.3.1 U.A.E Refractory Angina Market by Drugs
9.4.5.3.2 U.A.E Refractory Angina Market by Therapies
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Refractory Angina Market Overview
9.5.2 South and Central America Refractory Angina Market Forecasts and Analysis
9.5.3 South and Central America Refractory Angina Market Forecasts and Analysis - By Drugs
9.5.4 South and Central America Refractory Angina Market Forecasts and Analysis - By Therapies
9.5.5 South and Central America Refractory Angina Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Refractory Angina Market
9.5.5.1.1 Brazil Refractory Angina Market by Drugs
9.5.5.1.2 Brazil Refractory Angina Market by Therapies
9.5.5.2 Argentina Refractory Angina Market
9.5.5.2.1 Argentina Refractory Angina Market by Drugs
9.5.5.2.2 Argentina Refractory Angina Market by Therapies
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. REFRACTORY ANGINA MARKET, KEY COMPANY PROFILES
11.1. ARK THERAPEUTICS GROUP PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NEOVASC INC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. SANERON CCEL THERAPEUTICS, INC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. VASOMEDICAL, INC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. CRYOPRAXIS
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. WORKHARDT
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SYNOKEM
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GRANDIX PHARMACEUTICALS
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. BLUECROSS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. VIRGINIA SPINE INSTITUTE
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

- Ark Therapeutics Group plc
- Neovasc Inc
- Saneron CCEL Therapeutics, Inc
- Vasomedical, Inc
- Cryopraxis
- Workhardt
- Synokem
- Grandix Pharmaceuticals
- Bluecross
- Virginia Spine Institute